ND0612, a novel liquid formulation of levodopa/carbidopa for subcutaneous infusion in patients with Parkinson's disease achieves stable levodopa plasma levels when administered in low and high doses

被引：0
|
作者：
Giladi, Nir [1 ]
Caraco, Yoseph [2 ]
Gurevich, Tanya [3 ]
Djaldetti, Ruth [4 ]
Adar, Liat [5 ]
Cohen, Yael [5 ]
Minei, Tamar Rachmilewitz [5 ]
Oren, Sheila [5 ]
机构：
[1] Tel Aviv Med Ctr & Sch Med, Tel Aviv, Israel
[2] Hadassah Med Ctr, Jerusalem, Israel
[3] Sackler Sch Med, Tel Aviv, Israel
[4] Tel Aviv Univ, Petah Tiqwa, Israel
[5] NeuroDerm Ltd, Rehovot, Israel
来源：
NEUROLOGY | 2017年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S4.002
引用
收藏
页数：3
相关论文
共 39 条
  • [1] ND0612 (levodopa/carbidopa for subcutaneous infusion) achieves stable levodopa plasma levels when administered in low and high doses in patients with PD
    Giladi, N.
    Caraco, Y.
    Gurevich, T.
    Djaldetti, R.
    Adar, L.
    Minei, T. Rachmilewitz
    Oren, S.
    MOVEMENT DISORDERS, 2017, 32
  • [2] Relative bioavailability of levodopa administered as a subcutaneous infusion with ND0612 versus oral immediate-release levodopa/carbidopa tablets
    Adar, Liat
    Vostokova, Natalia
    NEUROLOGY, 2023, 100 (17)
  • [3] Relative bioavailability of levodopa administered as a subcutaneous infusion with ND0612 versus oral immediate-release levodopa/carbidopa tablets
    Adar, L.
    Vostokova, N.
    MOVEMENT DISORDERS, 2022, 37 : S438 - S439
  • [4] Ninety-day Local Tolerability and Toxicity Study of ND0612, a Novel Formulation of Levodopa/Carbidopa, Administered by Subcutaneous Continuous Infusion in Minipigs
    Ramot, Yuval
    Nyska, Abraham
    Maronpot, Robert R.
    Shaltiel-Karyo, Ronit
    Tsarfati, Yonit
    Manno, Rosa Anna
    Sacco, Giuseppe
    Yacoby-Zeevi, Oron
    TOXICOLOGIC PATHOLOGY, 2017, 45 (06) : 764 - 773
  • [5] Pharmacokinetic profile of continuous levodopa/carbidopa delivery when administered subcutaneously (ND0612) versus duodenal infusion (levodopa/carbidopa intestinal gel)
    Adar, L.
    Minei, T. Rachmilewitz
    Cohen, Y.
    Oren, S.
    MOVEMENT DISORDERS, 2017, 32
  • [6] Efficacy of Continuous Subcutaneous Levodopa/Carbidopa Infusion (ND0612) on Motor Signs of Parkinson's disease (PD) and Experiences of Daily Living
    Rascol, O.
    Isaacson, S.
    LeWitt, P.
    Poewe, W.
    Ferreira, J.
    Lopes, N.
    Sopromadze, S.
    Pereira, J.
    Olanow, C.
    MOVEMENT DISORDERS, 2024, 39 : S313 - S313
  • [7] Subgroup Analyses of a Phase 3 Randomized Study of Levodopa/Carbidopa Infusion (ND0612) for Parkinson's Patients
    Poewe, W.
    Espay, A.
    Lopes, N.
    Ferreira, J.
    MOVEMENT DISORDERS, 2024, 39 : S306 - S306
  • [8] Enrolment characteristics for patients entering a Phase 3 study of subcutaneous levodopa/carbidopa infusion with ND0612
    Rascol, O.
    Albanese, A.
    Ellenbogen, A.
    Ferreira, J.
    Gurevich, T.
    Hassin, S.
    Hernandez-Vara, J.
    Isaacson, S.
    Kieburtz, K.
    LeWitt, P.
    Manzanares, L. Lopez
    Olanow, C.
    Pahwa, R.
    Poewe, W.
    Sarva, H.
    Stocchi, F.
    Yardeni, T.
    Adar, L.
    Salin, L.
    Lopes, N.
    Sasson, N.
    Case, R.
    Espay, A.
    Giladi, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 708 - 709
  • [9] Pharmacokinetic and safety characterisation of carbidopa/levodopa subcutaneous infusion (ND0612): Phase I studies in healthy volunteers and patients with fluctuating Parkinson's disease
    Lewitt, P.
    Caraco, Y.
    Adar, L.
    Oren, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 514 - 514
  • [10] Continuous Subcutaneous Levodopa/Carbidopa Infusion with ND0612 For Parkinson's Disease: Three-year Data from the Openlabel BeyoND Study
    Poewe, W.
    Ellenbogen, A.
    Stocchi, F.
    Adar, L.
    Salin, L.
    Case, R.
    Yardeni, T.
    Giladi, N.
    MOVEMENT DISORDERS, 2023, 38 : S46 - S46
1234